2020
DOI: 10.1016/j.jacc.2020.05.001
|View full text |Cite
|
Sign up to set email alerts
|

Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19

Abstract: Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

34
984
10
65

Year Published

2020
2020
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 910 publications
(1,093 citation statements)
references
References 4 publications
34
984
10
65
Order By: Relevance
“…Apart from cases of pulmonary embolism, COVID-19 can cause a sepsis-associated DIC, which is defined as "sepsis-induced coagulopathy" (SIC) [169]. Thus, there is an increasing interest in anticoagulant therapy to treat COVID-19 [249].…”
Section: Anticoagulation As a Key Therapy For Covid-19mentioning
confidence: 99%
See 1 more Smart Citation
“…Apart from cases of pulmonary embolism, COVID-19 can cause a sepsis-associated DIC, which is defined as "sepsis-induced coagulopathy" (SIC) [169]. Thus, there is an increasing interest in anticoagulant therapy to treat COVID-19 [249].…”
Section: Anticoagulation As a Key Therapy For Covid-19mentioning
confidence: 99%
“…Apart from cases of pulmonary embolism, COVID-19 can cause a sepsis-associated DIC, which is defined as "sepsis-induced coagulopathy" (SIC) [169]. Thus, there is an increasing interest in anticoagulant therapy to treat COVID-19 [249]. In a retrospective analysis conducted at Tongji Hospital of Huazhong University of Science and Technology in Wuhan, the authors examined 449 patients affected by severe COVID-19 [228].…”
Section: Anticoagulation As a Key Therapy For Covid-19mentioning
confidence: 99%
“…Infection with SARS-CoV-2 results in a syndrome that ranges in severity from asymptomatic to multi-organ failure and death. In addition to local complications in the lung, the virus can cause systemic in ammation and disseminated micro thrombosis, which can cause stroke, myocardial infarction or pulmonary emboli [3][4][5][6] . Risk factors for poor COVID-19 outcome include advanced age, obesity, diabetes and hypertension 1,7-13 . Computational analyses can provide insights into the transmission, control, progression and underlying mechanisms of infectious diseases.…”
Section: Introductionmentioning
confidence: 99%
“…In COVID-19 subjects, an elevation in D-dimer is prominent, while thrombocytopenia and the prolongations of PT and APTT are milder [1][2][3] . Moreover, a high frequency of venous and arterial thromboembolism is observed, even in subjects with mild COVID-19 [4][5][6][7][8] . These unique patterns of laboratory data and the high incidence of thromboembolism suggest that coagulation abnormalities might exist in subjects with At present, several mechanisms have been proposed to explain the mechanism of abnormal coagulopathy observed in COVID-19 subjects.…”
Section: Introductionmentioning
confidence: 99%